We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock
ISEE

Delisted

ISEE was delisted on the 10th of July, 2023.

Back to rankings

52 hedge funds and large institutions have $21.2M invested in IVERIC bio, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less funds holding

Funds holding: 58 → 52 (-6)

10% less capital invested

Capital invested by funds: $23.7M → $21.2M (-$2.47M)

44% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 18

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

Holders
52
Holders Change
-6
Holders Change %
-10.34%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
10
Reduced
18
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$320K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$285K
3
Renaissance Technologies
Renaissance Technologies
New York
+$169K
4
BFM
Boothbay Fund Management
New York
+$128K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$117K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$309K
2
SIM
Spark Investment Management
New York
-$265K
3
BCM
Bridgeway Capital Management
Texas
-$243K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$167K
5
Two Sigma Investments
Two Sigma Investments
New York
-$128K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Bridgeway Capital Management
Texas
$53K -$243K -176,900 -81%
PAM
27
Panagora Asset Management
Massachusetts
$44K -$1.13K -824 -2%
Charles Schwab
28
Charles Schwab
California
$39K – – –
BIM
29
Bogle Investment Management
Massachusetts
$38K -$3.69K -2,691 -8%
Millennium Management
30
Millennium Management
New York
$37K -$35.1K -25,559 -48%
Russell Investments Group
31
Russell Investments Group
United Kingdom
$37K +$1.92K +1,400 +5%
Wells Fargo
32
Wells Fargo
California
$36K -$31.5K -22,945 -45%
SEI Investments
33
SEI Investments
Pennsylvania
$36K – – –
ARTA
34
A.R.T. Advisors
New York
$31K -$5.83K -4,250 -15%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$29K – – –
GF
36
Gabelli Funds
New York
$26K +$8.23K +6,000 +43%
Squarepoint
37
Squarepoint
New York
$16K +$17.2K +12,557 New
Citigroup
38
Citigroup
New York
$5K -$6.61K -4,820 -54%
KCPG
39
Kavar Capital Partners Group
Kansas
$5K +$4.8K +3,500 New
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$4K – – –
CG
41
Cutler Group
California
$2K – – –
EWM
42
Endurance Wealth Management
Rhode Island
$2K – – –
Federated Hermes
43
Federated Hermes
Pennsylvania
$1K -$99 -72 -10%
AP
44
Atwood & Palmer
Missouri
$1K – – –
Bank of America
45
Bank of America
North Carolina
$1K – – –
UBS Group
46
UBS Group
Switzerland
$1K – – –
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$53 -$26 -19 -32%
VF
48
Virtu Financial
New York
– -$60K -42,450 Closed
OAM
49
Oxford Asset Management
United Kingdom
– -$28K -19,947 Closed
TSS
50
Two Sigma Securities
New York
– -$23K -16,574 Closed
1
2
3

ISEE Hedge Fund Activity: Q2 2019 in Review

52 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2019, worth a combined $21.2M — down 10% from $23.7M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ISEE and 5 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 10 added.

The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $320K. The largest seller was Morgan Stanley, cutting an estimated $309K.

  • 52 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2019, down from 58 in Q1 2019.
  • Funds reported $21.2M of IVERIC bio, Inc. Common Stock stock for Q2 2019, down 10% quarter-over-quarter.
  • 5 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2019 and 11 closed out, a net change of -6 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q2 2019 was Assenagon Asset Management, an estimated $320K added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q2 2019 was Morgan Stanley, an estimated $309K sold.

Based on aggregated 13F filings for Q2 2019.